HDT Bio is a clinical-stage developer of RNA-based vaccines and therapeutics for infectious disease and oncology. With core intellectual property in nucleic acid formulation and delivery, the company pursues a business model of grants-funded discovery and early clinical development paired with industry collaborations, technology transfer, and commercialization. The LION formulation technology allows for flexible manufacturing, improved stability, and multiple routes of administration for nucleic acids.